process yielded products that consisted mainly of flanking intron sequences. Consequently, in designing primers one must compromise between the genomic locations that are optimal for PCR priming and those that are closest to the target sequence.
Finally, some questions remain regarding the ability of microdroplet PCR to amplify genomic loci with very high or very low GC content. It is unclear whether it will be possible to identify one set of reaction conditions that can be applied to all targets or whether it will be necessary to conduct multiple amplification reactions that would be combined before sequencing.
With the explosive development of secondgeneration sequencing technologies, rapid analysis of entire exomes or subsets of exomes is now feasible. Until the costs of wholegenome sequencing fall substantially, the study of genome sequences in large cohorts will require optimized methods for targeted DNA capture. The high uniformity of coverage and comprehensiveness provided by microdroplet PCR offers a valuable new approach for focused genome analysis. level of throughput is approximately one-tenth of that required for amplification of the human exome. The potential to increase the length of amplified products using long-range PCR is limited by the current requirement to shear the template DNA into 2-to 4-kb fragments, making the present version of the microdroplet method best suited for amplification of exon subsets (e.g., CAN genes, which are frequently mutated in tumors 2 ) or specific genomic loci in the megabase size range.
In addition, although microdroplet PCR appears to capture less off-target DNA and hence yields less unwanted sequence data than other target capture strategies [5] [6] [7] , it is limited by the need to amplify and sequence the flanking sequences of any target of interest. Indeed, the targeting of 457 exons for validation of the 99.1% of 2,390 comparisons, indicating a high level of accuracy for variant detection at this depth of sequencing. The authors conclude that the coverage and genotyping accuracy of microdroplet PCR is similar to that obtained using conventional PCR.
Comparisons of microdroplet PCR with other targeted capture methods are difficult, in part because previous studies used different targets (with different GC content and homologs in the genome) and different depths of sequencing coverage. Furthermore, it is not always known whether the probes and primers used for capture were chosen for optimal functionality. Nevertheless, the authors note that capture of off-target DNA and the accuracy of variant calling by their method are in the same range as those of enrichment strategies based on molecular inversion probes 5 , solution hybridization 6 or chip hybridization 7 ( Table 1) . Uniformity of coverage for the microdroplet PCR method permits a high variant detection rate at a given level of sequence coverage ( Table 1 , column 4).
The value of uniformity of coverage is determined largely by the relative costs of the capture and sequencing technologies. In other words, poor uniformity in the yield of captured DNA can often be salvaged by deeper sequencing if the sequencing costs are a minor component of the overall budget. Given that the capture efficiency and variant calling accuracy appear so similar for the different capture technologies, it is likely that the choice of one platform over another will largely be determined by their relative operational costs. The potential of microdroplet PCR to be highly automated should reduce labor costs. However, the relative costs of reagents for the different capture methods are at present unclear, particularly as some systems may be more amenable to multiplexing.
Preliminary data indicate that future runs of the microfluidic instrument might be scalable to 20,000 PCR products by including multiple primer pairs in each droplet. However, even this The microdroplet PCR approach of Tewhey et al. 1 was used to target a similar amount of genomic sequence as methods based on molecular inversion probes 5 and solution hybridization 6 (1-5 Mb), whereas a study that used chip hybridization 7 sequenced the majority of human protein-coding exons (~27 Mb). All data were obtained using the Illumina GA-II platform. The sequence coverage represents the generated sequence data that was used for mapping and was estimated from details provided in the references indicated.
A systems view of host defense

Daniel e Zak & alan aderem
Large-scale perturbations unravel the complex networks of activated dendritic cells.
The body's first line of defense against infection is the innate immune system, which recognizes conserved molecular patterns on microbes via receptors such as toll-like receptors (TLRs) 1 . TLRs transduce the information into pathogen-specific immune responses involving networks comprising ~2,000 genes 2 ( Fig. 1) . A new study by Amit et al. 3 in Science describes an important advance in elucidating these networks. By combining expression profiling and large-scale perturbations, the authors discover many novel regulators and interactions that might control the physiological processes induced by TLRs. These network components represent novel candidates for detailed analysis and potential targets for the development of vaccines and antimicrobial or anti-inflammatory drugs. Addressing the complexity of innate immunity requires the large-scale approaches of systems biology. Previous work has focused primarily on the responses of the transcriptome to TLR activation. Our group has studied these responses in macrophages, integrating transcription factor binding site analysis and dynamic computational modeling to identify small novel regulatory networks established regulators of the cell cycle (e.g., E2f5) or of circadian rhythms (e.g., Timeless) may moonlight as regulators of specific gene groups associated with antiviral responses is unexpected and compelling. It is highly unlikely that these novel interactions would have been discovered using conventional approaches.
This groundbreaking study does have a few limitations. First, after examining the effects of 125 regulators on 118 target genes, the authors conclude that nearly one-sixth of all possible interactions are significant, with 80% of the candidate regulators affecting four or more targets. By comparison, an earlier estimate based on forward genetic analysis is that ~50 genes in the entire genome play nonredundant roles in positively regulating TLR responses 8 . That so many of the candidate regulators suggested by Amit et al. 3 are found to control TLR responsive genes is, in our opinion, unrealistic. Second, Amit et al. 3 interpret their results in terms of the classical categories of 'antiviral' and 'inflammatory' responses, which does not take full advantage of a systems approach. The true power of systems biology lies in its ability to identify modules and networks directly from the data, extending beyond known signaling pathways. By casting their network in the canonical binary framework, predicted modules that do not fit neatly into either category are obscured. Finally, many of the network interactions, identified by gene knockdown instead of by direct measurements of transcription factor-promoter binding, are likely to be indirect.
That said, Amit et al. 3 have produced a herculean study that pushes the limits of the approach. However, the systems biology field as a whole suffers from an inability to directly link inferred gene networks to function. Fortunately, several emerging technologies are likely to fill this gap. The scale and quality of networks will improve dramatically when large-scale perturbations in primary cells 3 are coupled with next-generation sequencing 9, 10 . Multiplexed RNA-Seq and ChIP-Seq approaches will allow thousands of transcriptomes to be directly linked to genome-wide binding profiles of thousands of transcription factors. It will be straightforward to discriminate direct from indirect gene regulation and to interpret networks in the context of additional mechanisms of RNAdependent regulation, including alternative splicing and microRNA binding. Moreover, advances in high-throughput imaging and in microfluidics will allow much more precise definition of phenotype. Eventually, predictive networks linked to function will facilitate mine the microarray data to identify candidate regulators that act on target genes; systematically perturb each regulator with shRNAs and measure the effects on target gene responses to TLR activation; and construct a regulatory network from the perturbation data.
But if the concept is straightforward, its implementation is not. Knocking down individual genes in primary innate immune cells is notoriously difficult; knocking down >100 genes is a major accomplishment. Profiling the responses of target genes to the perturbations was facilitated by the nCounter system (from Nanostring Technologies), which enables highly parallel high-sensitivity transcript measurements from small amounts of sample.
In addition to finding well-established regulators of TLR responses (such as NF-κB, IRF, ATF and STAT family members), the authors identify many new factors that warrant further investigation. For example, the prediction that TLR4-induced Cbx4, a SUMO E3 ligase, negatively regulates the induction of IFNβ is intriguing. Similarly, the hypothesis that that were validated in vitro and in vivo 4, 5 . In this manner we showed that ATF3 is a negative regulator of TLR4 signaling 4 , whereas C/EBPd, in conjunction with NF-κB and ATF3, forms a circuit that discriminates between transient and persistent TLR4 signals 5 .
Yet these sub-networks explain only a tiny fraction of TLR responses. Earlier studies have generated global network models by integrating microarray profiles and promoter scanning 2, 6 , although they lacked experimental validation. More recently, Suzuki et al. 7 investigated an experimentally tractable systemthe differentiation of a macrophage-like cell line-and demonstrated the power of coupling computational network analysis with large-scale perturbations.
Amit et al. 3 have now taken another step in global network analysis of the TLR pathways by applying large-scale perturbation analysis to dendritic cells-innate immune cells that prime adaptive immune responses. Their approach is straightforward: profile the transcriptomes of TLR-activated dendritic cells; Kim Caesar
(such as 15 versus 12 copies). As a result, the relevance of higher-order CNVs to disease and phenotype generally goes untested in genome-wide association studies. In principle, experimental approaches that replace a noisy analog hybridization measurement with a digital count should offer more robust measurement of copy numbers for high-copy duplications. Indeed, approaches based on the read depth in next-generation sequencing data can infer CNV with greater quantitative and spatial precision compared with microarrays [9] [10] [11] [12] . However, most sequencing-based analyses to date have considered only the unique portions of the genome.
Alkan et al. 1 developed a sequence alignment method that is smarter at handling duplicated genomic segments. They realized that current alignment algorithms are confused by sequences present in multiple copies in the human genome reference sequence. Such 'multiread' sequences may align to multiple locations in the reference genome. Many alignment algorithms randomly assign a multiread to only one of its potential homes or give it a low mapping-quality score that causes it to get dropped altogether from downstream analyses. In contrast, the mrFAST (micro-read fast alignment search tool) aligner by Alkan et al. 1 reports all mapping locations for multireads (Fig. 1) . Its main technical advances include more efficient algorithms as well as data structures that keep track of mutations in multireads. Recording sequence variation makes it possible to distinguish between duplication regions in further analyses.
the translation of molecular interactions into therapies. In the particular case of dendritic cells, one might easily imagine how networks delineated by studying antigen presentation as a functional output could be reengineered to yield rationally designed vaccines.
